GAITHERSBURG, MD, USA I November 12, 2018 I MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life sciences company, announced today that it has entered into a research agreement with Kite, a Gilead Company. Under the terms of the agreement, Kite will use MaxCyte’s Flow Electroporation® Technology platform to enable non-viral cell engineering.
“We’re excited to provide Kite the ability to leverage our versatile cell engineering platform to enable gene-editing technologies for research and development of important new therapeutics,” said Doug Doerfler, President & CEO of MaxCyte, Inc. “This agreement further underlines MaxCyte’s position as a leader in non-viral cell engineering for cell therapies.”
About MaxCyte
MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology platform to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte’s mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, MaxCyte leverages its Flow Electroporation® Technology platform to enable its biopharmaceutical industry partners to advance the development of innovative, cutting-edge medicines, particularly in cell therapy, including the use of gene editing tools in the treatment of inherited genetic diseases and immuno-oncology approaches to treating cancer. MaxCyte has placed its cutting-edge flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies, has more than 55 partnered programme licences in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com.
SOURCE: MaxCyte
Post Views: 29
GAITHERSBURG, MD, USA I November 12, 2018 I MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life sciences company, announced today that it has entered into a research agreement with Kite, a Gilead Company. Under the terms of the agreement, Kite will use MaxCyte’s Flow Electroporation® Technology platform to enable non-viral cell engineering.
“We’re excited to provide Kite the ability to leverage our versatile cell engineering platform to enable gene-editing technologies for research and development of important new therapeutics,” said Doug Doerfler, President & CEO of MaxCyte, Inc. “This agreement further underlines MaxCyte’s position as a leader in non-viral cell engineering for cell therapies.”
About MaxCyte
MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology platform to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte’s mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, MaxCyte leverages its Flow Electroporation® Technology platform to enable its biopharmaceutical industry partners to advance the development of innovative, cutting-edge medicines, particularly in cell therapy, including the use of gene editing tools in the treatment of inherited genetic diseases and immuno-oncology approaches to treating cancer. MaxCyte has placed its cutting-edge flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies, has more than 55 partnered programme licences in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com.
SOURCE: MaxCyte
Post Views: 29
